Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep886 | Growth hormone IGF axis - basic | ECE2017

Nodular thyroid disease in acromegaly: cohort of 69 patients at a single institution

Alvarez-Escola Cristina , Gonzalez Diego Meneses , Dominguez Oscar Moreno , de la Morena Lucrecia Herranz

Materials and methods: The aims were to evaluate the frequency of nodular thyroid disease (NTD) in acromegalic patients and to correlate clinical and metabolic features with disease activity and other. We conducted a cross-sectional study including retrospectively 69 acromegalic patients attending to an University Hospital in Madrid, Spain between 1980 and 2016. Mean age was 63 (32–92) years, 63.8% of patients were female. Mean age at diagnosis of acromegaly was 48 (11&#1...

ea0022p565 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Daily temozolomide therapy in Nelson's syndrome

Ortiga Ruth Sanchez , Sanchez Victor L Gonzalez , Perez Oscar Moreno , Meana Andres , Alfonso Antonio A Pico

Temozolomide, an alkylating agent used in malignant gliomas, has been recently used too in the treatment of aggressive pituitary tumors. To date, two cases of Nelson’s syndrome has successfully treated with 5 days of 28-day cycle, but the follow-up has been shorter than 12 months. We reported the third patient with Nelson’s syndrome treated with temozolomide, who after an initial goal response to three 300 mg 5 days of 28-day cycles shown a clinical and biochemical (...

ea0049ep904 | Neuroendocrinology | ECE2017

Study of CHD7 gene in KAL 1-negative patients previously diagnosed with congenital hypogonadotropic hypogonadism that develop new pituitary deficiencies

Lecumberri Beatriz , Rodriguez Francisco Javier , Moreno Oscar , Santiago Manuel de , Nistal Manuel , Vallespin Elena , Campos Angel , Heath Karen

Introduction: Recent studies suggest that some patients initially diagnosed with congenital hypogonadotropic hypogonadism (CHH), may evolve towards a combined pituitary hormonal deficiency (CPHD). Heterozygous pathogenic CHD7 variants impair neural cell crest guidance causing CHARGE syndrome and have been associated with abnormal pituitary development/function/structure and isolated CHARGE features, including HH. We aimed to genotype CHD7 and phenotype thoroughly those adult p...

ea0022p597 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Contribution of the molecular biology to the study of the behaviour of pituitary adenomas

Sanchez-Tejada Laura , Sanchez-Ortiga Ruth , Niveiro Maria , Peiro Gloria , Moreno Oscar , Aranda Ignacio , Alfonso Antonio A Pico

Background: There is an increasing interest to find specific prognostic markers of the aggressive behaviour of some pituitary adenomas (PA). The most studied markers have been the immunohistochemical staining for Ki-67 and p53. The aim of this study was to evaluate the relevance as possible prognostic markers of growth factors (IGF1R), angiogenic factors (VEGF and his receptor) and new genes (PTTG) versus the immunohistochemical expression of Ki-67 and p53 in PA.<p class="...

ea0016p636 | Reproduction | ECE2008

Gonadotropin releasing hormone analogue in cyclophosphamide-induced premature gonadal failure prevention

Revert Paula , Moreno Oscar , Lopez-Gomez Juan Miguel , Sivera Francisca , Martinez Sandra , Perdiguero Miguel , Pascual Eliseo , Pico Antonio

Background: Premature ovarian failure (POF) due to cyclophosphamide (Cyc) therapy is well documented in systemic lupus erythematosus (SLE) patients. Studies show that the use of gonadotropin releasing hormone (GnRH) analogues appears to protect women from POF. We present our experience in SLE patients treated with triptorelin.Methods: Observational study of 15 women diagnosed of SLE who have received concomitant treatment with Cyc and GnRH analogues (tri...

ea0073aep103 | Calcium and Bone | ECE2021

F18-choline PET/CT for primary hyperparathyroidism localization

Lobo Ines , Rojas Patricia Martin , Paola Parra Ramírez , Oscar Moreno Dom&237;nguez , Cristina Álvarez Escolá

ObjectiveSurgery is the only curative treatment for primary hyperparathyroidism. Minimally invasive parathyroidectomy is superior in terms of cure and complication rates and is less costly than inpatient bilateral cervical exploration. Preoperative localization of parathyroid adenoma by imaging is a requirement for outpatient minimally invasive surgery. One of the most frequently used imaging techniques for parathyroid adenoma localization is Tc99m-sesta...

ea0090ep13 | Adrenal and Cardiovascular Endocrinology | ECE2023

Evaluating the diagnostic capacity of the saline infusion and captopril challengetests for primary aldosteronism

Gonzalez Isabella Mantellini , Valencia Sime Rogic , Soriano Ines Borrego , Perez Paula Vazquez , Moreno Rosa Maria Garcia , Catalan Arturo Lisbona , Vazquez Gumersindo Fernandez , Dominguez Oscar Moreno , Alcala Beatriz Barquiel , Larrauri Miriam Zapatero , Casaus Maria Luisa Gonzalez , Garcia Irene Aguilera , Valderrama Alexa Pamela Benitez , Lobo Ines , Escola Cristina Alvarez , Rojas-Marcos Patricia Martin , Ramirez Paola Parra

Introduction: Primary aldosteronism (PA) is the most common cause of secondary hypertension. Guidelines recommend a confirmatory test in the majority of suspected cases: oral sodium loading, saline infusion test (SIT), captopril challenge test (CCT), or fludrocortisone suppression test. The SIT and CCT are most commonly used in clinical practice to study autonomous aldosterone secretion.Objectives and Methods: We compared the CCT’s diagnosis perform...